Loading...
•
Dec 31, 2021
Y-mAbs Q4 2021 Earnings Report
Y-mAbs reported financial results for the fourth quarter and the full year ended December 31, 2021.
Key Takeaways
Y-mAbs reported fourth-quarter net revenues of $9.6 million, consisting of product revenues from DANYELZA sales. The company ended the year with $181.6 million in cash and cash equivalents.
Net revenues for the fourth quarter of 2021 were $9.6 million, derived from DANYELZA sales.
DANYELZA sales increased by 7.1% compared to the third quarter of 2021.
DANYELZA was delivered to 28 centers across the nation, an increase of four centers since the third quarter of 2021.
The company had approximately $181.6 million in cash and cash equivalents as of December 31, 2021.
Forward Guidance
Y-mAbs anticipates a BLA resubmission for omburtamab by the end of the first quarter 2022 and at the same time, the Company is advancing its antibody constructs through the clinic; predominantly DANYELZA, omburtamab, and the SADA constructs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...